System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Sherif F Nagueh is an expert in Cardiology at Houston Methodist (United States). As of October 2026, ScienceLeadR ranks Sherif F Nagueh in the top 1% of experts worldwide for Cardiomyopathies and Aortic Valve Disease. Sherif F Nagueh has authored 381 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 2 of them ongoing. SLR score: 1,670 (community average: 125). How the SLR is computed.

LeadR Profile

Sherif F Nagueh Houston Methodist United States
1 670 ScienceLeadR Reputation 1670

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Medical Imaging - Public Health - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2026
Source: PubMed

Houston Methodist

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 381

Citations

Citations: 47 613 1st author: 58 Last author: 95 Unique author: 37

Main journals

J Am Coll Cardiol 67
Circulation 53
J Am Soc Echocardiogr 35
JACC Cardiovasc Imaging 28
Am J Cardiol 16

Best Journals

Circulation 12
N Engl J Med 4
Eur Heart J 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Long-Term Outcomes in Adults With Excessive Left Ventricular Trabeculation: Reconstructed Kaplan-Meier Meta-Analysis.
PMID 42933362 — mortality		JACC Adv20260
Clinical Considerations in Management of Hypertrophic Cardiomyopathy in Pregnancy: JACC State-of-the-Art Review.
PMID 42524805 — pregnancy, arrhythmias, cardiac, cardiology, cardiomyopathy, hypertrophic, cardiomyopathies		J Am Coll Cardiol20261
Beyond the 15-mm Threshold: Toward Personalized Assessment of Left Ventricular Hypertrophy in Hypertrophic Cardiomyopathy.
PMID 42714358 — hypertrophy, left ventricular, hypertrophy, cardiology, cardiomyopathy, hypertrophic, cardiomyopathies		J Am Coll Cardiol20261
Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
PMID 42667274 — cardiomyopathy, hypertrophic, therapeutics, blood circulation, cardiomyopathies		Circulation Top journal20261
Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.
PMID 42663111 — exercise, heart failure, diastolic, cardiomyopathy, hypertrophic, cardiac myosins, therapeutics, blood circulation, cardiomyopathies		Circulation Top journal20261

Clinical Studies 13

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 5
N/A 3
Phase 2 2
Phase 1 1
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 8
Active not recruiting 3
Enrolling by invitation 1
Recruiting 1

By type:

Interventional 11
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 10

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894 — safety, multiple chronic conditions, tablets, cardiomyopathy, hypertrophic, cardiomyopathies		Phase 3Active not recruiting2023
Open label Extension Study to Evaluate the Long term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506 — safety, tablets, cardiomyopathy, hypertrophic, research, therapeutics, forests, cardiomyopathies		Phase 2/Phase 3Enrolling by invitation2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS